ClinicalTrials.gg

Program

tigulixostat

Also written as “Tigulixostat”, “LC350189 formulated capsule” and “IBI128”.

Its studies are mostly in Gout · Hyperuricemia, led by 2 companies.

Furthest: phase 3, since Oct 16, 202210 company-led studies, 1 open or runningNext primary completion: Apr 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LG Chem80 open or runningphase 3since Oct 16, 2022May 19, 2011none ahead
Innovent Biologics21 open or runningphase 3since Feb 3, 2026Jul 2, 2024Apr 30, 2027phase 3 · NCT07414394

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2011First study: phase 1 study in HyperuricemiaNew to LG ChemLG Chem · NCT01361646 · 129 enrolled · Korea, Republic of
  2. Apr 25, 2019Phase 2 study in GoutLG Chem · NCT03934099 · 156 enrolled · United States
  3. Aug 19, 20192 phase 1 studies in GoutLG Chem · NCT04070846, NCT04066712
  4. Jun 28, 2021Early phase 1 study in HyperuricemiaLG Chem · NCT04966325 · 37 enrolled · United States
  5. Oct 16, 20222 phase 3 studies in GoutLG Chem · NCT05586971, NCT05586958
  6. Dec 7, 2023Phase 1 study in GoutLG Chem · NCT06189404 · 24 enrolled · United States
  7. Jul 2, 2024Innovent Biologics's first study: phase 2 study in GoutNew to Innovent BiologicsInnovent Biologics · NCT06501534 · 84 enrolled · China
  8. Feb 3, 2026Phase 3 study in GoutPhase 3 reachedInnovent Biologics · NCT07414394 · 600 enrolled · China

Ahead

  1. Apr 30, 2027Primary completion: phase 3 study in GoutInnovent Biologics · NCT07414394

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07414394Gout · China3Active, not recruitingInnovent BiologicsApr 30, 2027600
NCT06501534Gout · China2CompletedInnovent BiologicsDec 13, 202484
NCT06189404Gout · United States1CompletedLG ChemNov 13, 202324
NCT05586971Gout · United States, Argentina, Australia and more3CompletedLG ChemMay 6, 20252,202
NCT05586958Gout · United States, Georgia, Philippines and more3CompletedLG ChemNov 4, 2024354
NCT04966325Hyperuricemia · United StatesEarly 1CompletedLG ChemDec 7, 202137
NCT04066712Gout · United States1CompletedLG ChemSep 12, 202037
NCT04070846Gout · United States1CompletedLG ChemMar 7, 20206
NCT03934099Gout · United States2CompletedLG ChemMay 3, 2021156
NCT01361646Hyperuricemia · Korea, Republic of1CompletedLG ChemJan 2013129

How it is read

Names in the registry

  • “Tigulixostat”, 4 entries
  • “LC350189 formulated capsule”, 1 entry
  • “IBI128”, 1 entry
  • “LC350189 200mg”, 1 entry
  • “LC350189 600mg”, 1 entry

Codes read as this program: IBI128.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
tigulixostat (LG Chem): development program | ClinicalTrials.gg